Clifford A. Hudis, MD: A Message From ASCO’s CEO
2024 ASCO Annual MeetingClifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; and DB07 on trastuzumab deruxtecan with or without palbociclib.
Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).
Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).